These 15 stocks are still showing momentum — and a market-beating edge

“Big mo” stock strategies have lost their advantage, but these companies display relative strength.

Market Watch • Nov 20, 2025

Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44

SAN DIEGO , Nov. 19, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its Managed Access Program (MAP) for investigational therapy delpacibart zotadirsen (del-zota) for eligible people with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44) in the United States. "We recognize the considerable needs facing the DMD44 community given there are no approved exon skipping therapies for this disease as well as the potential of del-zota based on the unprecedented data shown in our clinical studies," said Sarah Boyce, President and Chief Executive Officer of Avidity.

PRNewsWire • Nov 19, 2025

Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights

Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology programs into a new public company ("SpinCo") Clear path forward aligned with FDA following pre-BLA meeting for del-zota, with BLA submission planned for 2026 Del-zota one-year data demonstrated sustained muscle protection leading to meaningful improvement and reversal of disease progression across multiple key functional measures Strong balance sheet with ~$1.9 billion  in cash, cash equivalents, and marketable securities SAN DIEGO , Nov. 10, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today reported financial results for the third quarter ended September 30, 2025, and highlighted recent progress. "In October, we announced that Avidity entered into a definitive merger agreement with Novartis, which we believe maximizes value for our investors, accelerates the global reach of our innovative neuroscience pipeline, and advances even more possibilities for our innovative science," said Sarah Boyce, president and chief executive officer of Avidity.

PRNewsWire • Nov 10, 2025

Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates

Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $0.65 per share a year ago.

Zacks Investment Research • Nov 11, 2025

Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)

Avidity is at the forefront of an exciting new class of treatments. Avidity shareholders will receive consideration for an exciting spinoff before Novartis acquires Avidity.

The Motley Fool • Oct 31, 2025

Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for

Avidity Biosciences (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 30, 2025

RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity Biosciences, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avidity Biosciences, Inc. (NASDAQ: RNA) to Novartis for $72.00 per share in cash is fair to Avidity shareholders. Halper Sadeh encourages Avidity shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Avidity and its.

Business Wire • Oct 28, 2025

RNA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Avidity Biosciences, Inc. is Fair to Shareholders

Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights

GlobeNewsWire • Oct 28, 2025

Shareholder Alert: The Ademi Firm investigates whether Avidity Biosciences Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE , Oct. 28, 2025 /PRNewswire/ -- The Ademi Firm is investigating Avidity (Nasdaq: RNA) for possible breaches of fiduciary duty and other violations of law in its transaction with Novartis. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

PRNewsWire • Oct 28, 2025

Avidity Biosciences (RNA) Moves 42.4% Higher: Will This Strength Last?

Avidity Biosciences (RNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research • Oct 28, 2025